There is no absolute answer. However, if established, previously used excipients made in conformance with good manufacturing practice are used to formulate a new drug, the risk would seem to be minimized. If new excipients are to be used, availability from the supplier should be assured. A finished drug manufacturer, therefore, probably would be wise to purchase excipients made by firms with a good business history who are able to guarantee future deliveries.